Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

To Compare the Gastroprotective Effects and Pharmacokinetic Profile of PA Versus Enteric-Coated Aspirin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00442052
Recruitment Status : Completed
First Posted : March 1, 2007
Last Update Posted : March 1, 2007
Sponsor:
Information provided by:
POZEN

Brief Summary:
Primary: To compare the gastroprotective effects of a once-daily dose of PA 325 combination tablet combining 325 mg pH sensitive aspirin and 20 mg immediate release omeprazole versus a once-daily dose of 325 mg enteric coated aspirin utilizing Lanza scores from endoscopy findings in normal healthy volunteers.

Condition or disease Intervention/treatment Phase
Healthy Drug: aspirin Drug: omeprazole Phase 1

Detailed Description:

PA 325 is proposed for the reduction in the risk of aspirin-associated gastrointestinal (GI) adverse events in patients requiring daily aspirin. This study is designed as a Proof of Concept study to evaluate the gastroprotective effects, pharmacokinetic profile, and safety of PA 325 in healthy volunteers.

To compare the gastroprotective effects of a once-daily dose of PA 325 combination tablet combining 325 mg pH-sensitive aspirin and 20 mg immediate release omeprazole versus a once-daily dose of 325 mg enteric coated aspirin utilizing Lanza scores from endoscopy findings in normal healthy volunteers.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Investigator-Blinded, Randomized, Parellel Group Study to Compare the Gastroprotective Effects and Pharmacokinetic Profile of PA 325 Versus Enteric-Coated Aspirin.
Study Start Date : November 2006
Study Completion Date : January 2007

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. To compare the gastroprotective effects of a once-daily dose of PA 325

Secondary Outcome Measures :
  1. To evaluate the safety and GI tolerability including ulcerogenic potential, the pharmacokinetic profile, and the effect on gastric pH of PA 325


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. A subject will be eligible for inclusion in this study if all of the following criteria apply:

    • Subject is a male or non-pregnant female
    • Subject is 50-75 years of age
    • Subject does not currently smoke
    • Physical status within normal limits of age and consistent with observations at screening
    • BMI of 20-30 kg/m2
  2. Female subjects are eligible for participation in the study if they are of:

    • Non-childbearing potential (i.e., physiologically incapable of becoming pregnant); or,
    • Childbearing potential, have a negative pregnancy test (urine) at screening, and at least one of the following applies or is agreed to by the subject:

      • Complete abstinence from intercourse for at least 14 days prior to first dose of study medication, throughout the study, and for 30 days after completion of the study
      • Female sterilization or sterilization of male partner; or,
      • Hormonal contraception by oral route, implant, injectable, vaginal ring; or,
      • Any intrauterine device (IUD) with published data showing that the lowest expected failure rate is less than 1% per year;
      • Double barrier method (2 physical barriers or 1 physical barrier plus spermicide); or
      • Any other method with published data showing that the lowest expected failure rate is less than 1% per year
  3. Each subject must be able to understand and comply with study procedures required of a subject and is able and willing to provide written informed consent prior to any study procedures being performed

Exclusion Criteria:

  1. History of hypersensitivity to omeprazole or to another proton-pump inhibitor
  2. History of allergic reaction or intolerance to aspirin or any NSAIDs and/or subject has a history of NSAID-induced symptoms of asthma, rhinitis, and/or nasal polyps
  3. Participation in any study of an investigational treatment in the 4 weeks before Day 1 dosing
  4. Presence of uncontrolled acute or chronic medical illness, e.g. gastrointestinal disorder, diabetes, hypertension, thyroid disorder, depression and/or infection that would endanger a subject if they were to participate in the study
  5. Gastrointestinal disorder or surgery leading to impaired drug absorption
  6. Evidence of uncontrolled, or unstable cardio- or cerebrovascular disorder, which in the investigator’s opinion would endanger a subject if they were to participate in the study
  7. Schizophrenia or bipolar disorder
  8. Use of any concomitant medication not approved by the study physician during the washout period and during the study conduct
  9. Serious blood coagulation disorder including use of systemic anticoagulants
  10. Subjects who donated 50 to 499 mL of blood within 30 days and more than 499 mL within 56 days prior to dosing
  11. Subjects who, through completion of the study, would have donated in excess of:

    • 500 mL of blood in 14 days;
    • 1,500 mL of blood in 180 days;
    • 2,500 mL of blood in 1 year.
  12. Baseline endoscopy showing any gastric or duodenal mucosal abnormality (hemorrhages, ulcers or erosions)
  13. Gastric pH > 3 at screening
  14. Screening laboratory value for ALT, AST >2 times the upper limit of normal
  15. Estimated creatinine clearance < 30 ml/min
  16. Other than noted specifically, any screening laboratory value that is clinically significant in the investigator’s opinion and would endanger a subject if they were to participate in the study
  17. History of hepatitis B or C, a positive test for hepatitis B surface antigen, hepatitis C antibody, a history of HIV infection, or demonstration of HIV antibodies
  18. History of malignancy, treated or untreated, within the past 5 years, with the exception of successfully treated basal cell or squamous cell carcinoma of the skin
  19. Subjects who have previously been a screen failure in this study
  20. Subject has excessive alcohol use (> 2 units per day on average; for example 2 bottles of beer, two glasses of wine, 2 ounces of liquor/spirits), or recent history (in the past 3 months) suggestive of alcohol or drug abuse or dependence.
  21. Subject has ingested grapefruit or grapefruit juice within 10 days of dosing or will ingest grapefruit or grapefruit juice during the duration of the study.
  22. Positive illicit drug screen

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00442052


Locations
Layout table for location information
United States, North Carolina
POZEN
Chapel Hill, North Carolina, United States, 27517
Canada, Quebec
MDS Pharma Services
Montreal, Quebec, Canada, H4R2N6
Sponsors and Collaborators
POZEN
Investigators
Layout table for investigator information
Principal Investigator: Gaetano Morelli, MD MDS Pharma Services

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00442052    
Other Study ID Numbers: PA325-101
First Posted: March 1, 2007    Key Record Dates
Last Update Posted: March 1, 2007
Last Verified: February 2007
Keywords provided by POZEN:
Gastroprotective effects
Aspirin
Additional relevant MeSH terms:
Layout table for MeSH terms
Aspirin
Omeprazole
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors